目的运用中西医结合治疗化疗敏感的小细胞肺癌患者,观察辨证与辨病治疗化疗敏感的小细胞肺癌的临床疗效。方法本研究采用探索性的队列研究模式,纳入2013年10月—2015年12月期间就诊于中国中医科学院广安门医院及中国医学科学院肿瘤医院...目的运用中西医结合治疗化疗敏感的小细胞肺癌患者,观察辨证与辨病治疗化疗敏感的小细胞肺癌的临床疗效。方法本研究采用探索性的队列研究模式,纳入2013年10月—2015年12月期间就诊于中国中医科学院广安门医院及中国医学科学院肿瘤医院的初治的门诊小细胞肺癌患者。根据是否接受中医药治疗为暴露因素,分为中西医结合队列和西医队列。4～6周期化疗后进入随访阶段。研究的主要指标包括OS、PFS等;次要指标包括实体瘤疗效评价、中医症状评分改善情况等。结果中西医结合队列与西医队列比较:MST分别为24个月和20个月,mPFS分别为19个月和14个月;局限期中西医结合队列与西医队列比较:MST分别为25个月和22个月,mPFS分别为19个月和15个月;广泛期中西医结合队列与西医队列比较:MST分别为21个月和16个月,mPFS分别为11个月和7个月,差异均无统计学意义。疗后84、126 d,2组DCR差异具有统计学意义(P<0.05)。疗后42、84、126 d KPS评分变化情况,中西医队列优于西医队列(P<0.05)。2队列治疗前后临床症状疗效相比较,其中神疲乏力、气短、食欲不振、自汗盗汗、口干咽燥、胸闷、咳嗽、咯痰、便秘等9个症状,中西医队列优于西医队列(P<0.05)。在血液系统中性粒细胞及血红蛋白减少不良反应以及泌尿系统不良反应,肌酐不良反应等方面,中西医结合队列优于西医队列(P<0.05)。结论花宝金教授运用系列方药中西医结合治疗化疗敏感的小细胞肺癌,可以改善患者体力状况,缓解临床症状以及减轻血液系统和泌尿系统的不良反应,且在延长OS、PFS方面有一定作用,但仍需扩大样本量以验证。展开更多
Bt5198, a new rice restorer line containing Bt gene, was developed from the cross and backcross of the elite restorer line Chenghui 177 with Bt Minghui 63, a transgenic Bt restorer line. The inbred lines were evaluate...Bt5198, a new rice restorer line containing Bt gene, was developed from the cross and backcross of the elite restorer line Chenghui 177 with Bt Minghui 63, a transgenic Bt restorer line. The inbred lines were evaluated using PCR amplification, test paper evaluation, insect resistance evaluation in both the laboratory and paddy fields, nursery evaluation of rice blast resistance and pedigree selection of agronomic traits. Larval mortalities on Bt5198 and Bt Minghui 63 were 100% when rice culms were inoculated with the eggs of the striped stem borer （SSB） in the laboratory. Bt5198 was highly resistant against SSB and the yellow stem borer （YSB） under field conditions. The F1 hybrids derived from Bt5198 and four cytoplasmic male sterile （CMS） lines were also highly resistant to SSB and YSB and had a significant heterosis. Two-year evaluation of rice blast resistance confirmed that the resistance levels of Bt5198 to leaf blast and neck blast were similar to those of Chenghui 177 and significantly better than those of Bt Minghui 63. Seed germination ability and pollen yield of Bt5198 were similar with Chenghui 177, suggesting that the introduction of the Bt gene into the new restorer line had no significant effects on seed vitality or the yield of seed production. To identify the presence of the Bt gene, it was effective to combine test paper examination with the evaluation of insect-resistance, both in the laboratory and under field conditions.展开更多
Objective: To investigate the efficacy of integrated Chinese and Western medicine extending the progression-free survival(PFS) and overall survival(OS) of limited-stage small-cell lung cancer(LS-SCLC) patients after t...Objective: To investigate the efficacy of integrated Chinese and Western medicine extending the progression-free survival(PFS) and overall survival(OS) of limited-stage small-cell lung cancer(LS-SCLC) patients after the first-line chemoradiotherapy. Methods: The data of 67 LS-SCLC patients who received combined treatment of Chinese medicine(CM) and Western medicine(WM) between January 2013 and May 2020 at the outpatient clinic of Guang’anmen Hospital were retrospectively analyzed. Thirty-six LS-SCLC patients who received only WM treatment was used as the WM control group. The medical data of the two groups were statistically analyzed. Survival analysis was performed using the product-limit method(Kaplan–Meier analysis). The median OS and PFS were calculated, and survival curves were compared by the Log rank test. The cumulative survival rates at 1, 2, and 5 years were estimated by the life table analysis. Stratified survival analysis was performed between patients with different CM administration time. Results: The median PFS in the CM and WM combination treatment group and the WM group were 19 months(95% CI: 12.36–25.64) vs. 9 months(95% CI: 5.96–12.04), respectively, HR=0.43(95% CI: 0.27–0.69, P <0.001). The median OS in the CM and WM combination group and the WM group were 34.00 months(95% CI could not be calculated) vs. 18.63 months(95% CI: 16.43–20.84), respectively, HR=0.40(95% CI: 0.24–0.66, P<0.001). Similar results were obtained in the further stratified analysis of whether the duration of CM administration exceeded 18 and 24 months(P<0.001). Conclusion: The combination treatment of CM and WM with continuing oral administration of CM treatment after the first-line chemoradiotherapy for LS-SCLC patients produced better prognosis, lower risks of progression, and longer survival than the WM treatment alone.(Registration No. Chi CTR2200056616)展开更多
文摘目的运用中西医结合治疗化疗敏感的小细胞肺癌患者,观察辨证与辨病治疗化疗敏感的小细胞肺癌的临床疗效。方法本研究采用探索性的队列研究模式,纳入2013年10月—2015年12月期间就诊于中国中医科学院广安门医院及中国医学科学院肿瘤医院的初治的门诊小细胞肺癌患者。根据是否接受中医药治疗为暴露因素,分为中西医结合队列和西医队列。4～6周期化疗后进入随访阶段。研究的主要指标包括OS、PFS等;次要指标包括实体瘤疗效评价、中医症状评分改善情况等。结果中西医结合队列与西医队列比较:MST分别为24个月和20个月,mPFS分别为19个月和14个月;局限期中西医结合队列与西医队列比较:MST分别为25个月和22个月,mPFS分别为19个月和15个月;广泛期中西医结合队列与西医队列比较:MST分别为21个月和16个月,mPFS分别为11个月和7个月,差异均无统计学意义。疗后84、126 d,2组DCR差异具有统计学意义(P<0.05)。疗后42、84、126 d KPS评分变化情况,中西医队列优于西医队列(P<0.05)。2队列治疗前后临床症状疗效相比较,其中神疲乏力、气短、食欲不振、自汗盗汗、口干咽燥、胸闷、咳嗽、咯痰、便秘等9个症状,中西医队列优于西医队列(P<0.05)。在血液系统中性粒细胞及血红蛋白减少不良反应以及泌尿系统不良反应,肌酐不良反应等方面,中西医结合队列优于西医队列(P<0.05)。结论花宝金教授运用系列方药中西医结合治疗化疗敏感的小细胞肺癌,可以改善患者体力状况,缓解临床症状以及减轻血液系统和泌尿系统的不良反应,且在延长OS、PFS方面有一定作用,但仍需扩大样本量以验证。
基金supported by the grant from the National Research and Development Project of Transgenic Crops of Ministry of Science and Technology of China (Grant No.JY03-B-11)
文摘Bt5198, a new rice restorer line containing Bt gene, was developed from the cross and backcross of the elite restorer line Chenghui 177 with Bt Minghui 63, a transgenic Bt restorer line. The inbred lines were evaluated using PCR amplification, test paper evaluation, insect resistance evaluation in both the laboratory and paddy fields, nursery evaluation of rice blast resistance and pedigree selection of agronomic traits. Larval mortalities on Bt5198 and Bt Minghui 63 were 100% when rice culms were inoculated with the eggs of the striped stem borer （SSB） in the laboratory. Bt5198 was highly resistant against SSB and the yellow stem borer （YSB） under field conditions. The F1 hybrids derived from Bt5198 and four cytoplasmic male sterile （CMS） lines were also highly resistant to SSB and YSB and had a significant heterosis. Two-year evaluation of rice blast resistance confirmed that the resistance levels of Bt5198 to leaf blast and neck blast were similar to those of Chenghui 177 and significantly better than those of Bt Minghui 63. Seed germination ability and pollen yield of Bt5198 were similar with Chenghui 177, suggesting that the introduction of the Bt gene into the new restorer line had no significant effects on seed vitality or the yield of seed production. To identify the presence of the Bt gene, it was effective to combine test paper examination with the evaluation of insect-resistance, both in the laboratory and under field conditions.
基金the Science and Technology Innovation Project of the China Academy of Chinese Medical Sciences(No.CI2021A01808)the Natural Science Foundation of Beijing(No.7212189)the Outstanding Young Scientific and Technological Talents(Innovation)Training Program of China Academy of Chinese Medical Sciences(No.ZZ15-YQ-026)。
文摘Objective: To investigate the efficacy of integrated Chinese and Western medicine extending the progression-free survival(PFS) and overall survival(OS) of limited-stage small-cell lung cancer(LS-SCLC) patients after the first-line chemoradiotherapy. Methods: The data of 67 LS-SCLC patients who received combined treatment of Chinese medicine(CM) and Western medicine(WM) between January 2013 and May 2020 at the outpatient clinic of Guang’anmen Hospital were retrospectively analyzed. Thirty-six LS-SCLC patients who received only WM treatment was used as the WM control group. The medical data of the two groups were statistically analyzed. Survival analysis was performed using the product-limit method(Kaplan–Meier analysis). The median OS and PFS were calculated, and survival curves were compared by the Log rank test. The cumulative survival rates at 1, 2, and 5 years were estimated by the life table analysis. Stratified survival analysis was performed between patients with different CM administration time. Results: The median PFS in the CM and WM combination treatment group and the WM group were 19 months(95% CI: 12.36–25.64) vs. 9 months(95% CI: 5.96–12.04), respectively, HR=0.43(95% CI: 0.27–0.69, P <0.001). The median OS in the CM and WM combination group and the WM group were 34.00 months(95% CI could not be calculated) vs. 18.63 months(95% CI: 16.43–20.84), respectively, HR=0.40(95% CI: 0.24–0.66, P<0.001). Similar results were obtained in the further stratified analysis of whether the duration of CM administration exceeded 18 and 24 months(P<0.001). Conclusion: The combination treatment of CM and WM with continuing oral administration of CM treatment after the first-line chemoradiotherapy for LS-SCLC patients produced better prognosis, lower risks of progression, and longer survival than the WM treatment alone.(Registration No. Chi CTR2200056616)
